Aceto Corp Executive reported Insider selling to the SEC on Mar 8, 2016 in a Form 4 Filing. Hans C Noetzli , director of Aceto Corp sold 6,500 shares on Mar 8, 2016. The shares were sold at $22.91 per share for a total value of $148,936.45.
Currently the company Insiders own 3.7% of Aceto Corporation shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -10.69%.Institutional Investors own 87.15% of Aceto Corporation shares.During last six month period, the net percent change held by insiders has seen a change of -10.28%.
Aceto Corporation Last issued its quarterly earnings results on Feb 4, 2016. The company reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $0.30. The company had revenue of $131.67 million for the quarter, compared to analysts expectations of $132.71 million. The company’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.28 EPS.
Aceto Corporation: On Wednesday, Mar 9, 2016 heightened volatility was witnessed in Aceto Corporation which led to swings in the share price. The shares opened for trading at $22.6 and hit $23.07 on the upside , eventually ending the session at $22.65, with a gain of 0.27% or 0.06 points. The heightened volatility saw the trading volume jump to 1,09,442 shares. The 52-week high of the share price is $32.2 and the company has a market cap of $669 M . The 52-week low of the share price is at $18.03.
Aceto Corporation (Aceto) is engaged in marketing sales and distribution of finished dosage form generic pharmaceuticals nutraceutical products pharmaceutical active ingredients and intermediates specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products. The Company’s business is organized along product lines into three segments: Human Health Pharmaceutical Ingredients and Performance Chemicals. The Human Health segment includes finished dosage form generic drugs and nutraceutical products. The Pharmaceutical Ingredients segment has two product groups: Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Intermediates. The Performance Chemicals segment includes specialty chemicals and agricultural protection products. The Company has operations in China Germany France the Netherlands Singapore India Hong Kong Philippines the United Kingdom and the United States.